TRACE
Trace a source
tape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advicetape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advice
publisheddirectional thesisSHORTyoutubenot an explicit trade

LLY directional thesis

Most-favored-nation pricing forces US GLP-1 prices from $1,300 to ~$149, compressing pharma margins on blockbusters

$1,034entry snapshot
pendingcurrent snapshot
— pendingsince mention
“You could buy a GLP-1 drug for $1,300 in the United States and go to London, it sells for $88... we've got them to agree to most favored nation status pricing. That's going to radically lower the price of drugs.”
59:56claim_id mcl_23da97626918d3838fopen evidence ↗
Classification directional thesis

Human-reviewed public claim.

Evidence span 59:56

Evidence URL, source timestamp, and excerpt are attached to this permanent claim page.

Correction path available

Creators or reviewers can request reclassification, context, or entity corrections without erasing the source record.

Machine-readable claim
{
  "version": "market-claims.v1",
  "claim": {
    "id": "mcl_23da97626918d3838f",
    "url": "/trace/claims/mcl_23da97626918d3838f",
    "status": "PUBLISHED",
    "claimType": "DIRECTIONAL_THESIS",
    "direction": "SHORT",
    "claimText": "Most-favored-nation pricing forces US GLP-1 prices from $1,300 to ~$149, compressing pharma margins on blockbusters",
    "confidence": 0.72,
    "expert": {
      "slug": "allin",
      "displayName": "All-In Podcast",
      "kind": "PERSON",
      "status": "UNCLAIMED",
      "avatarUrl": "/api/avatars/acfd1290-a",
      "url": "/trace/experts/allin",
      "claimed": false
    },
    "primaryEntity": {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    },
    "evidence": {
      "evidenceUrl": "https://www.youtube.com/watch?v=DBlOJpT9Y1Y&t=3596s",
      "sourceUrl": "https://youtube.com/watch?v=DBlOJpT9Y1Y",
      "timecode": "59:56",
      "startMs": 3596000,
      "endMs": null,
      "excerpt": "You could buy a GLP-1 drug for $1,300 in the United States and go to London, it sells for $88... we've got them to agree to most favored nation status pricing. That's going to radically lower the price of drugs."
    },
    "performance": {
      "entryPrice": 1034.3582508164,
      "currentPrice": null,
      "returnPct": null,
      "relativePct": null,
      "method": "PASTE_AUTHOR_PRICE"
    },
    "resolutionStatus": "OPEN",
    "ambiguityNotes": null,
    "horizon": "multi-year",
    "isExplicitTrade": false,
    "notFinancialAdvice": true,
    "disclaimer": "AISO tracks public statements, not verified portfolio positions. This is not financial advice."
  },
  "expert": {
    "slug": "allin",
    "displayName": "All-In Podcast",
    "kind": "PERSON",
    "status": "UNCLAIMED",
    "avatarUrl": "/api/avatars/acfd1290-a",
    "url": "/trace/experts/allin",
    "claimed": false
  },
  "source": {
    "platform": "YOUTUBE",
    "title": "Supercharging a New FDA: Marty Makary on Science, Power & Patients",
    "sourceUrl": "https://youtube.com/watch?v=DBlOJpT9Y1Y",
    "publishedAt": "2026-01-15T19:50:35.000Z"
  },
  "evidence": {
    "evidenceUrl": "https://www.youtube.com/watch?v=DBlOJpT9Y1Y&t=3596s",
    "sourceUrl": "https://youtube.com/watch?v=DBlOJpT9Y1Y",
    "timecode": "59:56",
    "startMs": 3596000,
    "endMs": null,
    "excerpt": "You could buy a GLP-1 drug for $1,300 in the United States and go to London, it sells for $88... we've got them to agree to most favored nation status pricing. That's going to radically lower the price of drugs.",
    "quote": "You could buy a GLP-1 drug for $1,300 in the United States and go to London, it sells for $88... we've got them to agree to most favored nation status pricing. That's going to radically lower the price of drugs.",
    "speaker": "Marty Makary"
  },
  "entities": [
    {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    }
  ],
  "marketData": {
    "entry": {
      "price": 1034.3582508164,
      "currency": "USD",
      "observedAt": "2026-01-15T19:50:35.000Z",
      "method": "PASTE_AUTHOR_PRICE"
    },
    "current": null,
    "returnPct": null
  },
  "snapshots": [
    {
      "kind": "ENTRY",
      "symbol": "LLY",
      "assetClass": "EQUITY",
      "price": 1034.3582508164,
      "probability": null,
      "currency": "USD",
      "provider": "paste.trade",
      "providerSymbol": "xyz:LLY",
      "observedAt": "2026-01-15T19:50:35.000Z",
      "method": "PASTE_AUTHOR_PRICE",
      "returnPct": null,
      "relativePct": null
    }
  ]
}

AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.